Chemotherapy including targeted therapy | 185/218 (84.8%) | |||
---|---|---|---|---|
Use of trastuzumab- or lapatinib- based therapies | Trastuzumab | Lapatinib | Both | All |
1st line (n = 175) | 118 (67.4%) | 26 (14.9%) | 2 (1.1%) | 146 (83.4%) |
2nd line (n = 127) | 63 (49.6%) | 34 (26.8%) | 1 (0.8%) | 98 (77.2%) |
3rd line (n = 81) | 39 (48.1%) | 15 (18.5%) | 2 (2.5%) | 56 (69.1%) |
4th line (n = 48) | 23 (47.9%) | 9 (18.8%) | 2 (4.2%) | 34 (70.9%) |
5th line and more (n = 27) | 7 (25.9%) | 6 (22.2%) | None | 13 (48.1%) |
Radiotherapy | 200/218 (91.7%) | |||
Whole brain radiotherapy only | 166/218 (77.3%) | |||
1 cycle radiotherapy | 173/218 (86.8%) | |||
2 cycles radiotherapy (SRS boost or EBRT) | 25/218 (12.5%) | |||
Second SRS | 2/218 (1.0%) | |||
SRS only | 21/218 (9.6%) | |||
Both (whole-brain radiotherapy and SRS) | 13/218 (6.0%) | |||
Whole-brain radiotherapy 2D | 96/193 (49.7%) | |||
Whole-brain radiotherapy 3D | 97/193 (50.3%) | |||
Median fractions per patient | 10 (1–28) | |||
Neurosurgery | 29/218 (13.3%) | |||
Emergency unit visits | 159/218 (73%) | |||
Mean length of stay | 14.9 days (95% - CI 13.2-16.7) | |||
Median length of hospital stay (days, range) | 9 days (range 1–221) | |||
Mean number of complications leading to hospitalisation | 0.44 (95/218) |